The Morrison Government will provide immediate access to life-changing medicines on the Pharmaceutical Benefits Scheme (PBS) to help support people with cystic fibrosis, saving them and their families up to $250,000 per year. From 1 December 2019, the life-changing cystic fibrosis medicine Symdeko® will be listed on the PBS for patients with cystic fibrosis over the age of 12, who have specific gene mutations. The current listing of Orkambi® will also be expanded for children aged 2-5 years of age, allowing earlier access to this life changing medicine. Patients can gain access to Symdeko® and Orkambi® immediately, with the manufacturer agreeing to the Government’s request to provide early access, until the medicine is listed on the PBS on 1 December. This is expected to provide new or improved treatment options for up to 1,400 patients. People might otherwise pay up to $250,000 a year for Symdeko®, or for Orkambi®, but with the Government’s investment they will now only pay a maximum of $40.30 per script, with concessional people paying just $6.50. In Australia, one in 2,500 babies are born with cystic fibrosis, and there is currently no cure. Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time. A defective gene causes a thick, sticky build-up of mucus in the lungs, pancreas, and other organs. The average life expectancy for Australians with cystic fibrosis is 38, still less than half that of the average Australian. This is why it is so important to provide access to new medicines that can extend the lives of people with cystic fibrosis. The Pharmaceutical Benefits Advisory Committee (PBAC) recommended these medicines be listed on the PBS. PBAC is independent of Government by law and in practice. By law, the Federal Government cannot list a new medicine without a positive recommendation from PBAC. Unlike Labor, we are subsidising all drugs recommended by the independent medical experts. Since 2013, the Government has listed more than 2,200 new or amended items on the PBS. This represents an average of around 30 listings per month – or one each day – at an overall cost of around $10.6 billion. Our commitment to ensuring that all Australians can access affordable medicines remains rock solid. Our plan for a strong economy continues to deliver record funding for essential health services that saves lives. More information these new PBS listings: Symdeko® will be made available through the PBS for the treatment of people with cystic fibrosis who have two copies of the f508del mutation in the CFTR gene, and are 12 years or older. Symdeko will also be made available for people with cystic fibrosis who have only one copy of the f508del mutation, and have one other residual function mutation. The current listing of Orkambi®, used to treat people with cystic fibrosis who have two copies of the F508del mutation in the CFTR gene, will be expanded so that children can commence subsidised treatment from two years of age.